Arvinas

Targeting Cancer with a Novel Protein Degradation Platform

Arvinas, Inc. (New Haven, CT). Arvinas is developing novel therapeutics based on a protein degradation platform developed in the lab of Craig Crews, and licensed from Yale University. Co-investors include Canaan Partners, 5AM Ventures, Connecticut Innovations, OrbiMed, RA Capital, and New Leaf. Major collaborations are in place with Merck, Genentech, and Pfizer. Rob Bettigole was an observer on the board of directors.